Claims
- 1. A host cell producing a DNA encoding an antigen-combining protein produced by the method of:
providing DNA containing genes encoding antigen-combining proteins; inserting said DNA into a framework antibody vector; and introducing said DNA and antibody framework vector into a host cell.
- 2. The host cell of claim 1, wherein the host cell is prokaryotic.
- 3. The host cell of claim 1, wherein the host cell is eukaryotic.
- 4. The host cell of claim 3, wherein the host cell is an immortalized cultured mammalian cell.
- 5. The host cell of claim 4, wherein the immortalized cultured mammalian cell is a myeloma or plasmacytoma cell.
- 6. The host cell of Claim 1 wherein said DNA is introduced into the host cell by a method selected from the group consisting of: electroporation, calcium phosphate coprecipitation, protoplast fusion, viral infection, and cell fusion.
- 7. The host cell of claim 1, wherein the DNA containing genes encoding antigen-combining proteins encodes an antigen-combining protein selected from the group consisting of:
an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region.
- 8. The host cell of claim 1, wherein the antigen-combining proteins comprise antibodies.
- 9. Host cells producing antibodies, produced by a method comprising:
providing DNA comprising genes encoding antibodies; inserting the DNA into framework antibody vectors; and introducing said framework antibody vectors into host cells.
- 10. The host cells of claim 9, wherein said DNA comprises a vector.
- 11. The host cells of claim 10, wherein said vector is an expression vector.
- 12. The host cells of claim 9, wherein the host cells are prokaryotic.
- 13. The host cells of claim 9, wherein the host cells are eukaryotic.
- 14. The host cells of claim 13, wherein the host cells are an immortalized cultured mammalian cell line.
- 15. The host cells of claim 14, wherein the immortalized cultured mammalian cell line is a myeloma or plasmacytoma cell line.
- 16. The host cells of claim 9, wherein said DNA is introduced into the host cells by a method selected from the group consisting of: electroporation, calcium phosphate coprecipitation, protoplast fusion, viral infection, and cell fusion.
- 17. The host cells of claim 9, wherein the DNA containing genes encoding antibodies encodes immunoglobulin heavy chain variable regions or immunoglobulin light chain variable regions.
Priority Claims (1)
Number |
Date |
Country |
Kind |
PCT/US91/00209 |
Jan 1991 |
WO |
|
RELATED APPLICATIONS
[0001] This application is a continuation of, and hereby claims priority to and incorporates by reference in their entirety, co-pending U.S. patent application Ser. No. 09/798,720, filed on Mar. 2, 2001 which is a continuation of U.S. patent application Ser. No. 09/439,732, filed Nov. 12, 1999, now U.S. Pat. No. 6,303,313; which is a continuation of abandoned U.S. patent application Ser. No. 08/997,195, filed Dec. 23, 1997; which is a continuation of U.S. patent application Ser. No. 08/315,269, filed Sep. 29, 1994, now U.S. Pat. No. 5,780,225; which is a continuation of U.S. patent application Ser. No. 07/919,730, filed Jul. 24, 1992, now U.S. Pat. No. 5,284,555; which is a continuation of abandoned U.S. application Ser. No. 07/464,350, filed Jan. 11, 1990. This application also claims priority to and incorporates by reference PCT Application No. PCT/US91/00209, filed Jan. 10, 1991.
Continuations (6)
|
Number |
Date |
Country |
Parent |
09798720 |
Mar 2001 |
US |
Child |
10690396 |
Oct 2003 |
US |
Parent |
09439732 |
Nov 1999 |
US |
Child |
09798720 |
Mar 2001 |
US |
Parent |
08997195 |
Dec 1997 |
US |
Child |
09439732 |
Nov 1999 |
US |
Parent |
08315269 |
Sep 1994 |
US |
Child |
08997195 |
Dec 1997 |
US |
Parent |
07919730 |
Jul 1992 |
US |
Child |
08315269 |
Sep 1994 |
US |
Parent |
07464350 |
Jan 1990 |
US |
Child |
07919730 |
Jul 1992 |
US |